Novocure

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novocure reports robust Q4 performance and eyes market expansion

Novocure's Q4 2022 performance showcased strong revenue growth, positive clinical outcomes, and ongoing investments in research and development.
Despite facing challenges in achieving positive adjusted EBITDA and addressing analyst inquiries, the company's strengths in innovation and partnerships position it for future success.
Opportunities in driving adoption of TTFields therapy, expanding into new indications, and leveraging partnerships underscore Novocure's growth potential in the oncology market.
With a focus on strategic planning and execution, Novocure aims to continue its trajectory of success, supported by a solid financial foundation and commitment to innovation.

NovoCure excels in Q1 with strong revenue and trial outcomes

NovoCure's Q1 2023 call highlighted strong financial performance, successful trial outcomes, and strategic plans for growth and innovation, while also acknowledging challenges in market expansion and patient growth.

Novocure reports robust Q2 earnings, advances innovative cancer therapies

Novocure's Q2 2023 performance reflects strong revenue growth and a focus on advancing innovative cancer therapies, particularly highlighted by the successful LUNAR trial results.
While facing challenges in regulatory processes and market expansion, Novocure's strategic strengths lie in its leadership in developing novel treatments and commitment to clinical advancement.
The upcoming Phase III trials and strategic initiatives present opportunities for Novocure to solidify its position as a key player in the oncology space and drive future growth.

NovoCure reports robust Q3 earnings, eyes global expansion and clinical milestones

NovoCure's Q3 performance reflects strong revenue growth and progress in clinical trials, particularly in lung cancer and GBM. While facing challenges related to denied payments and upcoming trials, the company remains resilient with exciting opportunities for global expansion and continued success in the oncology market.

NovoCure reports robust Q4 earnings, eyes growth in cancer therapies

NovoCure's Q4 2023 performance reflects strong financial results, progress in clinical trials, and a focus on extending survival in aggressive cancers through innovative therapies.
The company's strengths lie in its leadership in cancer treatment innovation, solid financial position, and commitment to disciplined growth strategies.
Challenges include regulatory approvals, managing cash burn, and maintaining cost efficiency, while opportunities abound in expanding product portfolio and advancing clinical trials for improved patient outcomes.

NovoCure excels in Q1 with record patient adoption and revenue growth

NovoCure's Q1 2024 performance reflects strong patient adoption, revenue growth, and strategic financial decisions to support future expansion and innovation.
While facing challenges related to regulatory processes and market dynamics, NovoCure's focus on clinical advancements and financial stability positions it well for long-term success.
The company's strengths in innovative therapies, positive trial outcomes, and financial resilience offer a solid foundation for seizing growth opportunities and overcoming potential obstacles.

NovoCure reports robust Q2 performance and outlines growth strategies

NovoCure's Q2 performance reflects strong financial results, patient growth, and progress in clinical programs, positioning the company for continued success.
Clear objectives set for 2024 and confidence expressed by executives indicate a strategic focus on growth and innovation in cancer therapy.
While facing challenges in regulatory processes and market competition, NovoCure has opportunities to leverage its strengths in commercialization and clinical development for future expansion.

Novocure reports robust Q3 earnings, eyes growth in cancer treatments

Novocure's Q3 performance reflects solid financial growth and patient adoption, supported by a strong focus on innovative cancer treatments and clinical advancements.
While leadership transitions and reimbursement challenges exist, the company's strategic initiatives and pipeline progress position them well for future success and market expansion.
Overall, Novocure's commitment to extending survival in aggressive cancers, coupled with operational improvements and market opportunities, underpin a positive outlook for the company.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novocure has provided stellar returns over the last five years, now up 17 times. Recent positive news may keep its stock going up.

This Stock Just Popped 40%. Here's Why It Can Continue to Crush the Market

Over the past few months we have discussed why Novocure stock (NASDAQ: NVCR) was vulnerable to downside risk, given its large rally and a delay in clinical trials.

What's Next For Novocure Stock?

Twitter

Berry Petroleum Corp.

Cardlytics

Global Blood Therapeutics

OrganiGram Holdings Inc.

Synchrony Financial

Atlassian

YUM! Brands

With the trading day about halfway over, the broad markets were again somewhat mixed.

NovoCure, Synchrony, Twitter, Yum! and More Wednesday Afternoon Analyst Calls

NovoCure (NVCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

NovoCure (NVCR) Moves 49.6% Higher: Will This Strength Last?

The stock price of Novocure Ltd (NASDAQ: NVCR) increased by 49.63% yesterday. This is why it happened.

NVCR Stock: 49.63% Increase Explanation

The oncology specialist's investigational cancer treatment could be a game-changer.

Why Novocure Stock Skyrocketed Today

Vanguard Value ETF

Novocure Ltd (NASDAQ: NVCR) shares are trading higher after a data monitoring committee said the interim analysis of the company's Phase 3 LUNAR trial would be accelerated. NovoCure develops commercial-stage oncology operations involving therapies to cure critical tumors.

What's Going On With NVCR Stock And VTV Stock Today?

A trial examining the use of Novocure's tumor-treating field technology in non-small cell lung cancer patients could enroll fewer patients over a shorter period, based on recommendations by an independent committee.

Independent Monitors Suggest Shorter Timeline for Novocure's Lung Cancer Treatment

NovoCure Limited spiked as much as 65% on Tuesday to its highest since it listed in 2015 after the global oncology company gave an update on its phase three trial for the treatment of non-small cell lung cancer (NSCLC). The Jersey-based company on Tuesday announced that an independent data monitoring committee gave it the green light to recruit more patients for its phase three Lunar trial of tumor treating fields in stage four NSCLC.

NovoCure surges 65% to all-time high on upbeat review of its lung cancer treatment trial (NVCR)

NVCR stock is skyrocketing on Tuesday after cancer treatment firm Novocure received great news regarding its phase 3 tumor treatment trial. The post NVCR Stock: The Cancer Therapy News That Has Novocure Shares Skyrocketing Today appeared first on InvestorPlace.

NVCR Stock: The Cancer Therapy News That Has Novocure Shares Skyrocketing Today

An independent board gave Novocure the go-ahead on Tuesday to recruit fewer patients for a study in lung-cancer treatment. The news sent NVCR stock rocketing.

Novocure Stock Rockets As Experts Recommend Accelerating Cancer Study

Shares of Novocure Ltd. skyrocketed 80.7% toward a record high in premarket trading Tuesday, after the tumor treatment company said an independent data monitoring committee (DMC) said the interim analysis of a Phase 3 trial would be accelerated.

Novocure's stock rockets into record territory after upbeat DMC review of lung cancer treatment trial

The stock price of NovoCure Limited (Nasdaq: NVCR) increased by over 80% pre-market. This is why it happened.

NVCR Stock: Over 85% Increase Pre-Market Explanation

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR #lcsm--Novocure announced an update on its phase 3 pivotal LUNAR trial of TTFields in stage 4 non-small cell lung cancer following platinum failure.

Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure announced 26 presentations on Tumor Treating Fields suggesting broad applicability of Tumor Treating Fields at the AACR Annual Meeting 2021.

Novocure Announces 26 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2021 Suggesting Broad Applicability of Tumor Treating Fields

NovoCure invented a new type of cancer treatment based on TTF (tumor treating fields). They use electricity to disrupt the division of cancer cells. The company is working to expand use cases via FDA approval, which could drive growth for years to come.

NovoCure: An Underfollowed Gem

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure announced today that it will report financial results for the first quarter 2021 on April 29, 2021, before the U.S. financial markets open.

Novocure to Report First Quarter 2021 Financial Results

According to the Trefis Machine Learning Engine, which identifies trends in a company's stock price using over 15 years of historical stock data, returns for NVCR stock average around 5% in the next one-month (twenty-one trading days) period after experiencing a 5% fall in a week (five trading da.

Can Novocure Stock Rebound After 8% Drop In A Week?

In late December, we highlighted that the rally in Novocure stock appeared to be overdone. Yesterday, there were multiple developments around the company, including its Q4 results.

Novocure Stock Likely To Slide Further After Delays In Clinical Studies?

Between earnings and a market pullback, this week hasn't been easy. But reducing exposure helped protect our gains.

Selling Before NVCR Stock Earnings Captured Quick Gain

The company announced delays of several clinical studies, with one analyst also predicting slower growth ahead.

Why NovoCure Stock Sank Today

NovoCure Limited (NVCR) CEO Asaf Danziger on Q4 2020 Results - Earnings Call Transcript

Novocure on Thursday reported adjusted earnings of 5 cents per share on $143.95 million in sales for its fourth quarter. In response, NVCR stock skidded.

Novocure Stock Tumbles As Earnings Fall Short, Sales Come In Line

NovoCure (NVCR) delivered earnings and revenue surprises of -69.23% and -0.01%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

NovoCure (NVCR) Q4 Earnings and Revenues Miss Estimates

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR #earnings--Novocure today reported financial results for the quarter and full year ended December 31, 2020, and provided a company update.

News for Novocure Stock (NVCR)